Bure’s holding of shares in Xvivo Perfusion

After the hive-off from Vitrolife, Bure Equity AB (publ) (“Bure”) has sold 440,000 shares in Xvivo to the company’s CEO, Magnus Nilsson

Vitrolife’s former subsidiary Xvivo Perfusion AB (“Xvivo”) was today taken up for trading on NASDAQ OMX First North, and in the future will be reported as a new portfolio company in Bure.

Ahead of the listing of Xvivo, Bure has sold 440,000 shares in Xvivo to the company’s CEO, Magnus Nilsson. Bure’s shareholding in Xvivo after the transaction amounts to 5,138,245, which is equal to 26.3% of the number of shares outstanding in the company.

Bure Equity AB (publ)

For more information contact:

Andreas Berglin, CFO
Tel. +46 8 – 614 00 20

Bure is a listed investment company with ownership interests in Nordic companies. The current holdings consist of seven portfolio companies, of which four are listed.

PDF